FLUGEN, INC. is a clinical-stage vaccine company founded in 2007 with a mission to transform vaccine efficacy in respiratory diseases. The company's slogan, "Transforming vaccine efficacy in respiratory disease." encapsulates its core focus. Specializing in the Biotechnology, Health Care, and Pharmaceutical industries, Flugen, Inc. has recently received a significant $11.40M grant investment on 01 July 2021 from the U.S. Department of Defense.
FLUGEN, INC.
Transforming vaccine efficacy in respiratory disease.
Founded 2007
6 employees
Grant
Total: $71.35M
Biotechnology, Health Care +1
General Information
Company Name
FLUGEN, INC.
Founded Year
2007
Employees
6
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Grant
BounceWatch is an independent company data service, not affiliated with FLUGEN, INC.. To contact FLUGEN, INC., visit flugen.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About FLUGEN, INC.
Taxonomy: vaccine development, respiratory diseases, influenza, vaccine efficacy, biopharmaceutical, clinical-stage, seasonal influenza, pandemic influenza, vaccine technology, prevention, treatment, public health, clinical trials, immunization
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | $11.40M | 1 |
U.S. Department of Defense
|
01 Jul 2021 |
| Debt Financing | $5.60M | - |
|
25 Nov 2018 |
| Grant | $14.40M | - |
|
18 Oct 2017 |
| Debt Financing | $5.50M | - |
|
01 Aug 2017 |
| Series A | $2.00M | 4 |
|
11 Apr 2017 |
| Venture Round | $12.00M | 6 |
|
24 May 2016 |
| Series A | $9.42M | 4 |
|
25 Aug 2015 |
| Debt Financing | $3.23M | 3 |
|
30 May 2014 |
| Venture Round | $7.80M | 1 |
Fred Mancheski
|
21 Feb 2011 |
FLUGEN, INC. Alternatives & Competitors
View All Alternatives
FLUGEN, INC. vs
Enhancing Vaccine Efficacy and Expanding Global Access with Innovative, Needle-Free Transdermal Tech...
Grant
1 employees
Biotechnology, Health Care
FLUGEN, INC. vs
Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune dis...
Series B
Biotechnology, Health Care
FLUGEN, INC. vs
Osivax
France
Pioneering A New Class of Universal Vaccines
Grant
53 employees
Biotechnology, Health Care
Curevo Vaccine
ILiAD Biotechnologies
FAQ About FLUGEN, INC.
Transforming vaccine efficacy in respiratory disease.
FLUGEN, INC. was founded in 2007.
FLUGEN, INC. operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on vaccine development, respiratory diseases, influenza and vaccine efficacy.
FLUGEN, INC. has approximately 6 employees.
FLUGEN, INC. has completed 9 funding rounds, raising a total of $71.35M. The latest funding stage is Grant.
Top alternatives and competitors to FLUGEN, INC. include TheraJect, Inc., VentiRx Pharmaceuticals, Osivax, Atriva Therapeutics GmbH, Curevo Vaccine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FLUGEN, INC. and TheraJect, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for FLUGEN, INC., https://bouncewatch.com/company/flugen-inc, updated 9 November 2024. When citing, please name BounceWatch and link this page.
